Annual report pursuant to Section 13 and 15(d)

Note 1 - Organization and Summary of Significant Accounting Policies (Details Textual)

v3.23.1
Note 1 - Organization and Summary of Significant Accounting Policies (Details Textual) - USD ($)
12 Months Ended
Aug. 30, 2022
Dec. 31, 2022
Dec. 31, 2021
Patent and Trademark Costs   $ 327,263 $ 304,206
Previously Capitalized Patent Costs Abandoned   52,702 98,645
Amortization of Intangible Assets   47,590 40,151
Finite-Lived Intangible Asset, Expected Amortization, Year One   48,000  
Finite-Lived Intangible Asset, Expected Amortization, Year Two   48,000  
Finite-Lived Intangible Asset, Expected Amortization, Year Three   48,000  
Finite-Lived Intangible Asset, Expected Amortization, Year Four   48,000  
Finite-Lived Intangible Asset, Expected Amortization, Year Five   48,000  
Unrecognized Tax Benefits, Ending Balance   0 0
CRG Loan Agreement, Texas Case [Member]      
Litigation Settlement, Amount Awarded to Other Party $ 2,600,000    
Loss Contingency Accrual, Ending Balance   3,385,429  
Complaint By Dr. Goldberg Against Navidea and MT [Member]      
Estimated Litigation Liability   0  
Selling, General and Administrative Expenses [Member]      
Amortization of Intangible Assets   $ 47,590 $ 40,151
Minimum [Member]      
Finite-Lived Intangible Asset, Useful Life   5 years  
Maximum [Member]      
Finite-Lived Intangible Asset, Useful Life   15 years  
The 2014 Plan [Member]      
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized   7,750,000  
The 2014 Plan [Member] | Minimum [Member]      
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period   1 year  
The 2014 Plan [Member] | Maximum [Member]      
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period   4 years  
The 2002 and 2014 Plan [Member]      
Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period (Year)   10 years  
The 2002 and 2014 Plan [Member] | Grantee Status, Former Employee [Member]      
Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period (Year)   90 days  
Navidea Biopharmaceuticals Limited [Member]      
Noncontrolling Interest, Ownership Percentage by Parent   100.00%  
Macrophage Therapeutics [Member]      
Noncontrolling Interest, Ownership Percentage by Parent   99.96%  
Navidea Europe [Member]      
Noncontrolling Interest, Ownership Percentage by Parent   100.00%